News Medical

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

Albumedix Ltd, Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14 th March 2023, announce that Recombumin ® is a ...
Nasdaq

Sartorius to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions

- Recombinant human albumin is a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines - Sartorius ...
KTLA

Sartorius to acquire Albumedix, creating a powerhouse for innovative advanced therapy solutions

Through its combined forces, Sartorius and Albumedix will accelerate the availability of critical components for the manufacture of advanced therapies and next-generation biopharmaceuticals, globally.
WAVY-TV

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

Recombumin, an animal and human origin free recombinant albumin, is an excipient in the final formulation of Heartseed's HS-001 treatment. In February 2023, Heartseed announced successful dosing of HS ...